UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales

Nov.13.2025
UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales
According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.

Key Points

 

  • Sales of nicotine pouches in the UK reached 92 million units in 2022 and grew 55% in 2023.
  • Research shows teens can easily access these products and report sickness and fainting after use.
  • Nicotine content can reach up to 97.5mg per pouch, far higher than traditional nicotine replacement products.
  • Experts say packaging and marketing trends are attracting younger users.
  • The UK government has proposed banning sales to under-18s and limiting nicotine levels and flavours.

 


 

2Firsts, November 13, 2025 — According to The Guardian, health experts in the UK are increasingly concerned about the potential health effects of high-dose nicotine pouches as their sales continue to climb. Studies suggest that teenagers report nicotine rushes, sickness and fainting after using the products, while packaging and marketing appear to target younger audiences.

 

Nicotine pouches are widely visible in UK shops, displayed in colourful tins near chewing gum with flavours such as “frosty berry,” “lime storm,” and “Tomorrowland.” Marketed as “tobacco-free,” they nevertheless deliver substantial doses of nicotine.

 

The pouches differ from snus and vapes. Each sachet contains purified nicotine powder, cellulose fillers, flavourings and sweeteners, and is placed under the upper lip for absorption through the oral lining.

 

Since entering the UK market in 2019, nicotine pouches have rapidly expanded. Sales reached 92 million units in 2022 and rose 55% in 2023. Experts say this surge is partly due to revamped packaging that appeals to both adult smokers and younger groups. Prof Leonie Brose of King’s College London noted that the products have become more colourful and eye-catching in recent years.

 

Research shows adult experimentation with nicotine pouches doubled to 5.4% between 2020 and 2024, with 1% reporting regular use. Youth use appears similar and may be rising.

 

A study published this week in Addiction found that teenagers aged 14 to 16 in Scottish schools were familiar with nicotine pouches, describing them as easy to access and discreet. Pupils reported nicotine rushes, sickness and fainting, while teachers were largely unaware of their use.

 

US research shows similar trends. A review led by Dr Nargiz Travis at Georgetown University found that 35–42% of adolescents and young adults were aware of nicotine pouches, and 9–21% of non-tobacco users said they would consider trying them.

 

Health concerns focus on nicotine and the added flavourings. Nicotine is addictive and stimulates dopamine release in the brain’s reward pathways. Prof Barbara Sahakian of the University of Cambridge noted that high-dose products, especially those with high freebase nicotine levels, deliver nicotine more rapidly than cigarettes.

 

Nicotine pouch strengths range from 1.8mg to 97.5mg, far exceeding nicotine gum. Travis said high freebase nicotine levels allow faster absorption.

 

Concerns also relate to the possibility that users may transition to more harmful nicotine products. Young people may be particularly vulnerable due to ongoing brain development and increased nicotine receptor density during adolescence.

 

Users report gum irritation and stomach upset. Nicotine also increases heart rate and constricts blood vessels, posing risks for people with heart conditions.

 

Laboratory studies show pouch extracts may trigger stronger toxic and inflammatory cellular responses than pure nicotine, with flavourings suspected as the cause.

 

Despite risks, many experts maintain that nicotine pouches are significantly less harmful than cigarettes and could help some smokers quit. However, evidence for cessation effectiveness is limited, according to a Cochrane review led by Prof Jamie Hartmann-Boyce of the University of Massachusetts Amherst.

 

The UK government this week proposed banning sales of nicotine pouches to under-18s, capping nicotine levels and limiting flavours. Experts welcomed the move but said flavour regulation is complex, pointing to lingering menthol perception despite flavour bans.

 

Standardised packaging and neutral flavour naming may help deter youth without reducing adult interest, according to research by Dr Eve Taylor of King’s College London.

 

Researchers say the challenge is ensuring the product remains accessible to smokers who could benefit while preventing it from appealing to youth. Although pastel tins may seem harmless, they are engineered to deliver a highly addictive drug, raising concerns about a new generation of users.

 

Image source: The Guardian

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14